Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fulgent Genetics ( (FLGT) ) has shared an update.
On December 20, 2025, Fulgent Genetics’ subsidiary Inform Diagnostics signed agreements to buy all equity interests in Dermatopathology Experts (StrataDx) for $12.5 million and to acquire substantially all assets and certain liabilities of Bako Diagnostics’ dermatopathology, podiatric pathology, molecular diagnostic services and therapeutic products business for $43 million, for a total cash consideration of about $55.5 million, with closing targeted for the first half of 2026 subject to customary regulatory and closing conditions and mutual termination rights. The planned acquisitions will add CLIA- and CAP-accredited pathology laboratories in Georgia and Massachusetts, broaden Fulgent’s anatomic and dermatopathology test menu with proprietary PCR assays, nearly double its pathology salesforce, and deepen its national client base, reinforcing its push to become a one-stop diagnostic provider and to leverage its investments in AI-driven digital pathology to improve capacity, turnaround times and efficiency across its growing laboratory services platform.
The most recent analyst rating on (FLGT) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Fulgent Genetics’ overall stock score reflects a challenging financial performance with declining profitability and cash flow issues. However, positive earnings call insights and recent corporate events indicate potential for future growth. Technical indicators suggest moderate strength, but valuation remains a concern due to negative earnings.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics is a technology-based company operating a well-established laboratory services business and a therapeutic development arm, offering technical lab and testing services with physician interpretation while also developing nanoencapsulated targeted cancer therapies, as it aims to evolve from a diagnostic provider into a fully integrated precision medicine company.
Average Trading Volume: 276,133
Technical Sentiment Signal: Buy
Current Market Cap: $853.5M
Find detailed analytics on FLGT stock on TipRanks’ Stock Analysis page.